1Poynard T,Leroy V,Cohard M,et al.Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration[].Hepatology.1996
3Wills RJ.Clinical pharmacokinetics of interferons[].Clinical Pharmacokinetics.1990
4Reddy RK,Layden T,Poulakos J.Daily or twice daily interferon alfacon-1 (INFERGEN) administration achieves potimal viral suppression compared to thrice weekly dosing schedules in subjects with genotype 1 chronic hepatitis C virus (HCV) infection[].Hepatology.1999
5Schalm SW,Weiand O,Hansen BE,et al.Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patients data of six controlled trials[].Gastroenterology.1999
4BAILON P,PALLERONI A,SCHAFFER CA,et al.Rational design of a potent,long-lasting form of interferon:a 40 kDa branched polyethylene glycol-conjugated interferon -2a for the treatment of hepatitis C[J].Bioconjug Chem,2001,12(2):195-202
5LAMB M W,MARTIN N E.Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a[J].Ann Pharmacother,2002,36(5):933-935
6POCKROS P J,CARITHERS R,DESMOND P,et al.Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C:a multicenter,randomized controlled trial [J].Am J Gastroenterol,2004,99 (7):1 298-1 305
7FRIED M W,SHIFFMAN M L,REDDY K R,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J].Nat Eng J Med,2002,347 (13):975-982
8HADZIYANNIS S J,SETTE H J R,MORGAN T R,et al.Peginterferon -alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Inter Med,2004,140(5):346-355
9CHALASANI N,MANZARBEITIA C,FERENCI P,et al.Peginterferon alfa-2a for hepatitis C after liver transplantation:two randomized,controlled trials[J].Hepato,2005,41 (2):289-298
10TORRIANI F J,RODRIGUEZ-TOORRES M,ROCKSTROH J K,et al.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients[J].N Eng J Med,2004,351(5):438-450
